| Identification | Back Directory | [Name]
FTIDC | [CAS]
873551-53-2 | [Synonyms]
FTIDC
4-[1-(2-fluoropyridin-3-yl)-5-methyltriazol-4-yl]-N-methyl-N-propan-2-yl-3,6-dihydro-2H-pyridine-1-carboxamide
4-[1-(2-Fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-3,6-dihydro-N-methyl-N-(1-methylethyl)-1(2H)-pyridinecarboxamide
1(2H)-Pyridinecarboxamide, 4-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-3,6-dihydro-N-methyl-N-(1-methylethyl)- | [Molecular Formula]
C18H23FN6O | [MDL Number]
MFCD30182250 | [MOL File]
873551-53-2.mol | [Molecular Weight]
358.41 |
| Hazard Information | Back Directory | [Uses]
FTIDC is a highly potent and selective metabotropic glutamate receptor (mGluR) 1 antagonist and has possible therapeutic potential in animal models as well as humans. | [in vivo]
FTIDC (i.p. or p.o.; 1-30 mg/kg) reduces the duration of face-washing behavior elicited in a dosedependent manner and the inhibitory effect is statistically significant at 10 and 30 mg/kg with i.p. and 30 mg/kg with p.o.[1]. | Animal Model: | Male CD1 (ICR) mice of 6-weeks-old[1] | | Dosage: | 1, 3, 10, and 30 mg/kg | | Administration: | I.p. or p.o. | | Result: | Reduced the duration of face-washing behavior elicited in a dosedependent manner and was statistically significant at 10 and 30 mg/kg with i.p. and 30 mg/kg with p.o..
|
| [IC 50]
mGluR1a: 5.8 nM (IC50); mGlu5: 6200 nM (IC50) | [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|